Blood Screening Market Report 2026

The blood screening market size has grown rapidly in recent years. It will grow from $3.44 billion in 2025 to $3.84 billion in 2026 at a compound annual growth rate (CAGR) of 11.6%. The growth in the historic period can be attributed to increasing regulatory screening requirements, expansion of blood donation volumes, rising prevalence of transfusion-transmitted infections, growth of centralized blood banks, adoption of elisa-based testing.

The blood screening market size is expected to see rapid growth in the next few years. It will grow to $5.93 billion in 2030 at a compound annual growth rate (CAGR) of 11.5%. The growth in the forecast period can be attributed to increasing investments in advanced screening technologies, rising demand for rapid and accurate diagnostics, expansion of molecular testing adoption, growing integration of ai-driven data analysis, increased focus on global blood safety standards. Major trends in the forecast period include increasing adoption of nucleic acid testing technologies, rising demand for high-throughput screening systems, growing use of automated blood screening instruments, expansion of software-integrated screening platforms, enhanced focus on transfusion safety.

The rising prevalence of chronic diseases is anticipated to drive the growth of the blood screening market. Chronic diseases are long-term conditions or illnesses that are generally manageable but not curable, requiring adjustments to both the treatment used and the demands of the condition. Blood screening ensures the compatibility between the donor's and recipient's blood types during transfusions. Blood transfusions are often essential in the medical management of various chronic diseases, including autoimmune disorders, hematological conditions, and cancers of all types. For example, in September 2023, the World Health Organization, a Switzerland-based specialized agency of the United Nations, reported 41 million deaths annually, accounting for 74% of deaths caused by non-communicable diseases (NCDs) or chronic diseases worldwide. Consequently, the increasing prevalence of chronic diseases is fueling the growth of the blood screening market.

Major companies in the blood screening market are focusing on developing technologies such as liquid biopsy to improve early cancer detection, enhance treatment monitoring, and support personalized medicine approaches. A liquid biopsy is a minimally invasive test that examines blood or other body fluids to detect cancer cells or tumor-derived genetic material. For example, in November 2023, Guardant Health, Inc., a US-based biotechnology company, introduced Shield blood-based screening tests. The Shield test examines cell-free DNA (cfDNA) in the bloodstream, which may indicate the presence of colorectal tumors or precancerous growths. It specifically detects changes in DNA fragments released into the blood by cancer cells.

In March 2023, Werfen, a Spain-based specialized in vitro diagnostics company, acquired Immucor, Inc. for an undisclosed amount. Through this acquisition, Werfen intends to expand its diagnostics portfolio by incorporating Immucor’s transfusion and transplant product lines, strengthening its position in the blood-preparation and transfusion diagnostics market while extending its global presence in specialized diagnostics. Immucor, Inc. is a U.S.-based transfusion and transplant diagnostics company recognized for its in vitro diagnostics solutions that support patient-donor compatibility in blood transfusion and transplantation.

Major companies operating in the blood screening market are Abbott Laboratories, Grifols S.A., Becton Dickinson and Company, F. Hoffmann-La Roche AG, bioMérieux S.A., Bio-Rad Laboratories Inc., Thermo Fisher Scientific Inc., Ortho Clinical Diagnostics Inc., Beckman Coulter Inc., Siemens Healthineers AG, DiaSorin S.p.A., Merck KGaA, PerkinElmer Inc., Bio-Techne Corporation, Roche Diagnostics GmbH, Danaher Corporation, Sysmex Corporation, GenMark Diagnostics Inc., QIAGEN N.V., Hologic Inc., Luminex Corporation, Trinity Biotech plc, Fujirebio Inc., OraSure Technologies Inc., Immunetics Inc., Cepheid Inc., Haemonetics Corporation, Verax Biomedical Inc.

North America was the largest region in the blood screening market in 2025. The regions covered in the blood screening market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the blood screening market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the blood screening market by increasing costs of imported reagents, testing kits, automated analyzers, sequencing systems, and laboratory software solutions. Blood banks and diagnostic laboratories in North America and Europe are most affected due to reliance on imported high-precision screening technologies, while Asia-Pacific faces cost pressure on instrument manufacturing and exports. These tariffs are raising testing costs and slowing technology upgrades. However, they are also encouraging domestic reagent production, regional equipment assembly, and long-term strengthening of local blood screening capabilities.

The blood screening market research report is one of a series of new reports that provides blood screening market statistics, including blood screening industry global market size, regional shares, competitors with a blood screening market share, detailed blood screening market segments, market trends and opportunities, and any further data you may need to thrive in the blood screening industry. This blood screening market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Blood screening is a process used to examine blood, plasma, or blood components for transfusion or incorporation into blood products. It is employed to detect antibodies or tumor markers, identify disease-causing agents or symptoms, or assess the effectiveness of treatments.

The primary products in blood screening include reagents and kits, instruments, software, and services. Reagents are substances or compounds that facilitate reactions for detecting or measuring components or for preparing products due to their chemical or biological activity, while kits are test kits that can be utilized in laboratory settings or in the field to identify specific compounds in a sample. The technologies involved include nucleic acid testing, enzyme-linked immunosorbent assay (ELISA), rapid tests, western blot assays, and next-generation sequencing (NGS), and the process is carried out in blood banks, diagnostic centers, pathology labs, hospitals, clinics, and ambulatory surgical centers (ASCs).

The blood screening market consists of revenues earned by entities by providing transcription mediated amplification (TMA) and real-time PCR. The market value includes the value of related goods sold by the service provider or included within the service offering. The blood screening market also includes sales of analyzers, photo colorimeter, flame photometer, hemoglobin meter, blood roller mixer, dry bath incubators, and differential blood counter. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.